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Fas (also known as Apo-1 and CD95) receptor
has been suggested to control T cell expansion
by triggering T cell-autonomous apoptosis.
This paradigm is based on the extensive lym-
phoproliferation and systemic autoimmunity in
mice and humans lacking Fas or its ligand.
However, with systemic loss of Fas, it is unclear
whether T cell-extrinsic mechanisms contribute
to autoimmunity. We found that tissue-specific
deletion of Fas in mouse antigen-presenting
cells (APCs) was sufficient to cause systemic
autoimmunity, implying that normally APCs
are destroyed during immune responses via a
Fas-mediated mechanism. Fas expression by
APCs was increased by exposure to microbial
stimuli. Analysis of mice with Fas loss restricted
to T cells revealed that Fas indeed controls au-
toimmune T cells, but not T cells responding to
strong antigenic stimulation. Thus, Fas-depen-
dent elimination of APCs is a major regulatory
mechanism curbing autoimmune responses
and acts in concert with Fas-mediated regula-
tion of chronically activated autoimmune T cells.
INTRODUCTION
Naive T cells are activated by two signals provided by an-
tigen-presenting cells (APCs): an antigen and a costimula-
tory signal induced by microbial activation of pattern-rec-
ognition receptors (PRRs) (Janeway, 1989). As a result,
activated T cells proliferate, clear an infection, and disap-
pear, whereas memory T cells persist. Negative regulation
of activated T cells is ascribed to a T cell-autonomous
activation-induced cell-death (AICD) mechanism that in-
volves tumor necrosis factor receptor family members in-
cluding Fas (also known as Apo-1 or CD95) (Nagata and
Golstein, 1995). The importance of this mechanism has
been established because of systemic autoimmunity inlpr/lpr or gld mice with a mutant Fas-encoding gene
(lymphproliferation) (Watanabe-Fukunaga et al., 1992) or
Fas-Ligand (FasL)-encoding gene (general lymphoproli-
ferative disorder) (Lynch et al., 1994; Takahashi et al.,
1994), respectively, as well as in humans with lympho-
proliferative diseases (Fisher et al., 1995; Rieux-Laucat
et al., 1995; Wu et al., 1996). In addition, studies of T
cell-autonomous cell death in vitro (Brunner et al., 1995;
Dhein et al., 1995) provided support for the paradigm of
Fas-mediated AICD as a major regulator of T cell clonal
contraction and autoimmunity. However, because T cell
clonal contraction elicited by a bacterial superantigen
has been shown to be Fas independent (Hildeman et al.,
2002), the mechanisms of Fas involvement in autoimmu-
nity became unclear. Moreover, the studies of systemic
loss of Fas expression could not exclude the involvement
of Fas-mediated death of cell types other than T cells in
the prevention of autoimmunity. Earlier studies provided
some evidence that Fas-negative non-T cells contribute
to development of systemic autoimmunity: restoration of
Fas expression by T cells abolished lymphoproliferation
but not the production of autoantibodies (Fukuyama
et al., 1998), whereas deletion of B cells from lpr/lpr
mice led to diminished proliferation of T cells (Shlomchik
et al., 1994). A reasonable explanation for these findings
would be that the ‘‘other cell types’’ are in fact APCs. Ac-
cording to such a scenario, Fas-positive APCs should be
removed by activated T cells under normal circum-
stances, and the whole process is likely to work as a
negative regulatory loop, driving the contraction of T cell
responses. However, Fas-negative APCs expressing
autoantigens would sustain activation of self-reactive T
cells. The disappearance of dendritic cells (DCs) upon ac-
tivation of T cells has been documented before (Ingulli
et al., 1997; Wong and Pamer, 2003). Moreover, DCs
with a lifespan extended by transgenic overexpression
of a viral caspase inhibitor (Chen et al., 2006) caused sys-
temic autoimmunity. For such a regulatory mechanism to
be specific, APCs should be preconditioned for destruc-
tion during their maturation.
In order to test whether autoimmunity can be controlled
by Fas-mediated destruction of APCs, we sought theImmunity 26, 629–641, May 2007 ª2007 Elsevier Inc. 629
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Fas Is Required for Elimination of APCsFigure 1. Fas Expression by DCs Is Regulated by Signaling through PRRs
(A–C) DCs (CD11chi cells) were isolated from peripheral lymph nodes and stained for Fas without stimulation (red line) (A) or after in vivo stimulation with
LPS (red line) or CpG (blue line) (B). Black line indicates control CD11chi cells from a Fas knockout (FasKO)mice. Fas expression in unstimulated DCswas
compared in CD11b+ cells (thick black line) and CD8+ DCs (thick blue line). Thin lines (C) indicate corresponding populations in a FasKO mouse.
(D) Plasmacytoid DCs (PDCA-1+, CD11clo, B220+ cells) were stained for Fas before activation (thick black line) and after overnight stimulation in vivo with
LPS (thick red line) or CpG (thick blue line). Thin lines indicate corresponding populations in a FasKO mouse.
(E) In vivo activated Fas+ CD11chi DCs were stained for costimulatory molecule CD86 (thick red line). Thick black line indicates CD86 expression by non-
activated CD11chi cells; thin lines indicate respective controls (no antibody).
(F–H) BMDCs (CD11chi cells) were treated overnight in vitro with LPS (thick red lines) or type I interferon (thick blue lines) and stained with Fas (F, G) or
CD86 (H) antibodies. Thick black line indicates unstimulated BMDCs. Thin lines indicate negative controls without Fas antibodies (F, G) or CD86-stained
nonstimulated BMDCs (H). All plots from a representative experiments from at least three independent experiments. Plots (F) and (G) are from the same
experiment; thus, the negative control curves are the same.answers to three related questions. (1) Does PRR-induced
maturation of APCs predispose them to Fas-mediated
destruction? (2) Does APC-specific inactivation of Fas sig-
naling lead to systemic autoimmunity? (3) What is the real
role of Fas-mediated AICD of T cells in autoimmunity and
post-antigen clonal contraction? We found that Fas ex-
pression was indeed induced in DCs by microbial stimuli
and that removal of Fas from APCs led to development
of systemic autoimmunity. Although Fas expressed by T
cells was not important for T cell clonal contraction after
stimulation with strong antigens, it contributed to preven-
tion of systemic autoimmunity.
RESULTS
Fas Expression by APCs
The elimination of APCs by activated T cells through Fas
requires Fas expression by APCs. It is also likely to require
that Fas expression be inducible through PRR to ensure
that elimination is specific for mature APCs presenting
cognate antigen. For these reasons, Fas expression by
DCs was tested both in vivo and in vitro. DCs, freshly iso-
lated from peripheral lymph nodes, contained a fraction of
cells expressing a high amount of Fas (Figure 1A), whereas
injection of lipopolysaccharide (LPS) or unmethylated oli-
gonucleotides (CpG) led to uniform upregulation of Fas by
DCs (Figure 1B). Fas-expressing DCs were CD11chi,
CD11b+, whereas the majority of CD11chiCD8+ DCs were
Fas negative or Faslo (Figure 1C). Fas expression by plas-
macytoid DCs (pDCs), defined as PDCA-1+, CD11clo,
B220+ cells, was also inducible by LPS and CpG after
an overnight exposure in vivo (Figure 1D). As expected,
CD11chi, Fas+ cells expressed markers of activation630 Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc.such as the inducible costimulatory molecule CD86 (Fig-
ure 1E) and high amounts of MHC class II (not shown).
Bone-marrow-derived DCs (BMDCs) were found to
express Fas and to further induce Fas expression after
overnight exposure to LPS or type I interferon (Figure 1F;
Figure S1 in the Supplemental Data available online).
Expression of Fas correlated with overall DC activation
as determined by measuring expression of CD86 (Fig-
ure 1I). Thus, Fas expression by DCs can be induced by
triggering of PRRs (Toll-like receptors) or by type I inter-
feron, the production of which is normally induced by a
viral infection.
DC-Specific Deletion of Fas
To investigate the importance of Fas expression by APCs
and T cells for systemic autoimmunity, we produced mice
in which Fas was deleted specifically in APCs (DCs or B
cells) or in T cells (all T cells, or recently activated T cells).
Exon IX of the Fas gene encoding the death domain was
flanked with loxP recognition sites for the Cre recombi-
nase (‘‘floxed’’), similar to previously described mice
(Hao et al., 2004; see Figure S2 showing the targeting
strategy). The resulting mice (Fas knockin, FasKI) were
crossed to animals expressing Cre recombinase con-
trolled by promoters of the genes encoding the following
proteins: CD11c (CD11c-Cre, ‘‘floxed’’ genes deleted in
DCs), CD19 (CD19-Cre, deletion in B cells) (Rickert
et al., 1997), p56lck (proximal Lck-Cre, deletion in all T
cells) (Hennet et al., 1995), and granzyme B (GZB-Cre, de-
letion restricted to activated T cells) (Jacob and Baltimore,
1999).
The CD11c-Cre transgenic mice were produced via the
CD11c genomic promoter and enhancer (Brocker et al.,
Immunity
Fas Is Required for Elimination of APCsFigure 2. Deletion of Fas from DC in CD11c-Cre.FasKI Mice
(A) GFP expression was tested in total CD11chi lymph node cells from CD11c-Cre strains 4272 (blue line) and 4097 (red line). Black line: Cremouse.
(B–D) GFP expression in CD11c-Cre mouse strain 4097 was tested in CD11chi, CD11b+ cells (blue line) and CD11chi, CD8+ cells (green line) (B),
pDCs (red line) (C), and in T cells (CD4++CD8+ cells, blue line) or B cells (red line) (D). Black lines indicate control staining of cells from nontransgenic
littermates.
(E–G) Fas expression was determined in GFP+ DCs from the spleens of 4272 CD11c-Cre.FasKI mice (blue line) (E) and in LPS-treated BMDC and in
CpG-treated pDC isolated from 4097 CD11c-Cre.FasKI (red lines) ([F] and [G], respectively). Thick black lines indicate control CD11c-Cre+ Fas-
sufficient cells. Thin black lines indicate cells from FasKO mice used as negative controls.
(H–J) LPS-activated CD11c+, GFP+ BMDCs from control 4097 CD11c-Cre mice (H) and CD11c-Cre.FasKI mice (I) incubated overnight with control
CT26 (blue line) or human FasL-transfected CT26-95L carcinoma cells (black line) were stained with propidium iodide. Cytotoxicity was calculated
with the formula (a  b/a)3 100%, where a and b are percent of live CD11c+GFP+ cells incubated with FasL-negative and FasL-positive CT26 cells,
respectively. 67.1% ± 11.3% of Cre-negative BMDCs and 26.7% ± 3.0% of CD11c-Cre.FasKI BMDCs were killed. Mean from three experiments ±
SE, p = 0.03.
(K) LPS-activated, peptide-loaded splenic DCs were exposed to OT-1 T cells in vivo and cytotoxicity was calculated with the formula 100%3 (a b)/a,
where ‘‘a’’ is a ratio between DCs incubated with the cognate peptide (CFSEhi cells) and DCs treated with an irrelevant peptide (CFSElo cells) before
injection of the mixture into mice, and ‘‘b’’ is their ratio after exposure to T cells. Mean of four individual animals per group ± SE is shown. 24.8% ±
4.9% of B6 peptide-positive DCs and 0.7% ± 3.3% of lpr/lpr peptide-positive DCs were killed.
(L) Equal numbers of BMDCs from indicatedmicewere activated in vitro with LPS, labeled with two concentrations of CFSE, and exposed to activated
OT-1 (black bars) or FasL.KO OT-1 T cells (open bars) in the presence of specific peptide (CFSEhi cells) or without specific peptide (CFSElo cells),
mixed, and analyzed by flow cytometry. Cytotoxicity was calculated with the formula 100% 3 (a  b)/a, where ‘‘a’’ is a ratio of CFSElo to CFSEhi
BMDCs incubated without T cells, and ‘‘b’’ is the ratio of the same cells incubated with T cells. Mean of three parallels ± SE from a representative
experiment.
(M–O) DC accumulation was measured in the spleens of 6-month-old strain 4272 CD11c-Cre-FasKI mice and their Cre-negative littermates (three
animals per group compared in the same experiment, p = 0.006) (M), and in the 5-month-old 4097 CD11c-Cre.FasKI mice (N and O). Four animals
of each type were compared. Bars represent mean values ± SE. p values were 0.1 and 0.035 in (N) and (O), respectively.1997). The Cre transgene was also coexpressed (via an
IRES) with green fluorescent protein (GFP) to report its ex-
pression by flow cytometery. Several transgenic strains
were generated with different patterns of GFP expression.
CD11c-Cre strain 4272 showed GFP expression in a frac-tion of DCs (Figure 2A), whereas another strain (4097) had
GFP expression in themajority of DCs (Figure 2A). In strain
4097, all CD11chi cells expressed GFP (expected to have
equimolar expression with Cre) in both CD11chi, CD11b+
cells and CD11chi, CD8+ cells (Figure 2B). PlasmacytoidImmunity 26, 629–641, May 2007 ª2007 Elsevier Inc. 631
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Fas Is Required for Elimination of APCsFigure 3. Accelerated Development of
GVH Reaction in Recipient Mice with
Fas-Negative APC
NOD.scid or NOD.scidlpr/lpr recipients were in-
oculated i.p. with 23 107 splenocytes of MHC-
compatible B6g7 mice. ANA were detected by
staining of HEp-2 cells with sera samples di-
luted 1:100. ANA values are shown for individ-
ual mice (6–13 animals per group). Relative
scale (examples shown on the right): 0, normal
8-week-old B6 mouse serum; 10, serum of 1-
year-old B6lpr/lpr mouse. See also Figure S4
for explanation of ANA evaluation.DC (PDCA-1+, CD11clo, B220+) expressed lower GFP
(Figure 2C), as expected for CD11c-regulated expression.
T and B cells did not express GFP (Figure 2D).
Although only a fraction of CD11c+ DCs in strain 4272
expressed detectable amounts of GFP, any effects on
the immune system caused by Fas elimination from DCs
were expected to be cell autonomous. Thus, it should
not matter whether Fas was deleted in all or a fraction of
DCs. We therefore studied mice derived from both
founders. Fas expression was eliminated from subsets
of DCs in both 4272 and 4097 CD11c-Cre strains crossed
to FasKI mice (Figures 2E–2G).
To show that the loss of Fas resulted in resistance of
CD11c-Cre.FasKI DCs to a death signal delivered by
FasL, two types of experiments were performed. First,
BMDCs stimulated with LPS were exposed to CT26 carci-
noma cells transfected with human FasL (CT26-95L). As
expected, loss of Fas triggered by CD11c-Cre made
DCs resistant to FasL-mediated apoptosis in vitro (Figures
2H–2J). Second, LPS-activated, specific peptide-loaded
splenic DCs were labeled with 1 mM fluorescent dye
CFSE and mixed with control DCs (loaded with irrelevant
peptide) labeled with a lower concentration of CFSE
(0.1 mM), and the mixture was injected into footpads of
B6 mice. The next day, OT-1 T cells responsive to the
ovalbumin (OVA)-derived peptide (SIINFEKL) presented
by the MHC class I molecule Kb were injected i.v. into
the samemice, and the ratio between differentially labeled
DCs in the popliteal lymph nodes was established 48 hr
later, allowing us to measure killing of SIINFEKL-loaded
DCs. Under these experimental conditions, about 25%
of B6-derived DCs were killed, whereas there was no kill-
ing of DCs obtained from B6lpr/lpr mice (Figure 2K). Thus,
Fas-deficient DCs were also resistant to killing in vivo by
cognate OT-1 T cells. Importantly, killing of activated
DCs in vivo was antigen specific.
BecauseDCs treatedwith high dose of LPSwere shown
to express Fas ligand (FasL) (Chen et al., 2006), we asked
whether the actual killing of DCs is performed by T cells or
whether the presence of T cells is required for suicide by
FasL+ DCs. Equal numbers of DCs stained with CFSE
were cultured with LPS and with (CFSEhi) or without
(CFSElo) the SIINFEKL peptide, in the presence of acti-
vated OT-1 T cells or activated FasL-deficient OT-1 T cells
(Figure 2L). DCswere thenmixed and analyzed by flow cy-
tometry. Clearly, BMDC killing required FasL expression
by T cells. Addition of nonactivated OT-1 T cells did not632 Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc.lead to killing of DCs (not shown). Thus, the major contri-
bution to DC elimination through Fas-mediated killing
was delivered by activated antigen-specific T cells.
Abrogation of Fas-mediated apoptosis of DCs was
likely to result in their extended lifespan. Indeed, Fas-
negative DCs accumulated with age in the spleens of
both 4272 and 4097 CD11c-Cre.FasKI mouse strains
compared to Fas-sufficient littermates (Figures 2M–2O).
Finally, to test the hypothesis that the lack of APC elim-
ination by activated T cells enhances immune responses,
we used mice carrying the lpr mutation crossed to mice
lacking an adaptive immune system (scid mice) (Custer
et al., 1985).When suchmice are injectedwith spleen cells
from normal MHC-matched, minor histocompatibility anti-
gen-mismatched mice, the development of graft versus
host (GVH) response ensues. Recipient scid mice cannot
respond to the graft, whereas their APCs (DCs and possi-
bly macrophages) should be able to activate donor T cells.
By using anti-nuclear antibodies (ANA) as a fast and reli-
able read-out for GVH development, we expected that
ANA should developmore efficiently in scidlpr/lpr recipients
than in Fas-sufficient scid recipients, because Fas-nega-
tive APCs are more resistant to direct elimination by donor
T lymphocytes. We found that, indeed, ANA were de-
tectable much earlier in NOD.scidlprlpr recipients of B6g7
congenic splenocytes (Figure 3) than in Fas-sufficient
NOD.scid animals (NOD mice were used simply because
the appropriate combination of backgrounds was avail-
able). Although at the later time points ANA accumulated
to saturation in both types of recipients (not shown), the
APCs resistant to Fas-mediated death clearly induced ac-
celerated GVH. Thus, these findings support the idea of a
negative regulatory loop based on Fas-mediated elimina-
tion of APCs by T cells recognizing antigens presented
by these APCs.
Loss of Fas Expression by APCs Leads
to Systemic Immunity
Activated APCs express costimulatory signals and may
simultaneously express self-antigens. These two signals
can trigger autoreactive T cells. Should a negative-feed-
back loop of APC elimination through Fas be inactivated
by deletion of Fas, autoimmunity is likely to develop.
Thus, CD11c-Cre.FasKI mice were studied for signs of
autoimmunity. Lack of Fas expression specifically by
DCs resulted in several manifestations of systemic
autoimmunity: production of high titers of ANA,
Immunity
Fas Is Required for Elimination of APCshyperimmunoglobulinemia, splenomegaly, and histologi-
cal changes in spleen and liver. Some mice had elevated
ANA as early as 8 weeks of age, and by 12–16 weeks of
age, the majority of CD11c-Cre.FasKI mice showed high
amounts of ANA, unlike their Cre-negative FasKI litter-
mates (Figure 4A; Figure S5). In addition to production of
ANA, total amounts of both IgG (Figure 4B) and IgM
(Figure 4B; Figure S6) were elevated in mice lacking Fas
expression in DCs. These manifestations of autoimmunity
were found to be very similar in both females and males.
GFP-positive DCs accumulating in CD11c-Cre.FasKI
mice expressed high amount of CD86 costimulatory mol-
ecules (Figure 4C), indicating that these cells have under-
gone maturation. The CD11c-Cre.FasKI mice developed
splenomegaly (Figure 4D), associated with the loss of fol-
licular architecture (Figure 4E). The localization of DC was
also abnormal: similar to previously reported changes in
lpr/lprmice (Fields et al., 2001), DCswere spread through-
out the periarteriolar lymphoid sheath (Figure 4E). In addi-
tion, polymorphic infiltrates were found around central
veins in the liver. These infiltrates (Figure 4F) included
CD11c-positive DCs and various leukocytes. Thus, Fas
removal from DCs led to their accumulation and to sys-
temic autoimmunity.
B cells function as effector cells producing antibodies,
but also serve as another major APC subset. CD19-
Cre.FasKI mice (both females and males) (Figure 5A)
showed splenomegaly resulting from extensive lympho-
proliferation (Figure 5B). Importantly, the accumulating
cells were not composed exclusively of B cells, but also
included T cells (Figure 5C). Both T cell and B cell subsets
were polyclonal: T cells expressed a variety of T cell
receptor Vb chains, whereas B cells carried diverse rear-
ranged immunoglobulin heavy chains and demonstrated
a normal ratio of k and l light chains (data not shown). In
addition to lymphoproliferation, the loss of Fas by B cells
resulted in systemic autoimmunity as documented by pro-
duction of ANA (Figure 5D; Figure S5), development of
hyperimmunoglobulinemia (Figure S6), and, as previously
reported, production of anti-DNA antibodies (Hao et al.,
2004). Taken together, these observations suggest that
Fas-negative B cells serving as APCs fail to be eliminated
by activated T cells and, thus, sustain survival of autoim-
mune T cells and produce autoantibodies.
Fas-Dependent Regulation of T Cells Is Limited
to Self-Reactive T Cells
Wehave found that the loss of Fas expression by APCs led
to systemic autoimmune reactions. This mechanism reca-
pitulates some of the features of systemic immunity ob-
served in lpr/lpr mice. Another hallmark feature of lpr/lpr
phenotype is accumulation of double-negative T cells
lacking coreceptors but expressing the B cell marker
B220 (CD3+B220+ cells). These cells did not accumulate
in CD11c-Cre.FasKI or CD19-Cre.FasKI mice (see below),
indicating that their persistence must be a T cell-autono-
mous feature. Thus, we faced an obvious question of
whether Fas receptor expressed by T cells truly plays
the role it has been assigned in downregulating normalimmune responses (‘‘clonal contraction’’) and in autoim-
munity. To address these questions, we used mice with
selective Fas loss in all T cells or with such loss restricted
to recently activated T cells. FasKI micewere crossedwith
Cre driven by the proximal Lck (Hennet et al., 1995) or
Granzyme B (GZB) (Jacob and Baltimore, 1999) pro-
moters, respectively.
First, we addressed the issue of Fas participation in
clonal contraction of normal immune responses. We rea-
soned that should the T cell-autonomous Fas-mediated
AICD be the sole or major mechanism by which T cell
clonal expansion is regulated in vivo, secondary T cell re-
sponses in mice lacking Fas expression by T cells should
exceed such responses in mice with Fas-sufficient T cells.
Several experimental systems were used. In one series of
experiments, Lck-Cre.FasKI mice with T cell-specific de-
letion of Fas (Figure 6A) and the control Cre-negative
FasKI mice were immunized with OVA, and the response
of CD4+ T cells was tested 11 days later by ELISPOT assay
tomeasure the frequency of interferon-g (IFN-g)-secreting
cells (Figure 6B). The responses of Lck-Cre+ FasKI mice
were not higher than the responses of Cre-negative FasKI
littermates, suggesting that Fas was not a factor downre-
gulating T cell responses. Similarly, in another system,
Fas-negative, recently activated CD8+ T cells (in GZB-
Cre.FasKI mice carrying the OT-1 T cell receptor trans-
gene) did not demonstrate any advantage over Fas-suffi-
cient cells in response to antigen delivered by Listeria
monocytogenes (Lm-OVA) within the same test animal
(Figure 6C). Fas-sufficient and Fas-deficient T cells also
generated identical secondary responses to challenge
with Lm-OVA (data not shown). Finally, similar observa-
tions were made in GZB-Cre.FasKI mice responding to
the minor histocompatibility antigen H60 (Figure 6D).
H60-specific responses of CD8+ cells in individual mice
were traced by staining with specific tetramers. Because
there is no primary response on day 4 after immunization,
only recall responses are compared at day 4 after second-
ary immunization. Neither the slopes of the contraction of
primary responses nor the magnitude of secondary re-
sponses (day 4 after secondary immunization) were differ-
ent in Fas-sufficient and Fas-deficient mice.
These results indicated that the loss of Fas by both
helper 1-type (Th1) CD4+ T cells and CD8+ T cells does
not provide themwith a selective advantage over Fas-suf-
ficient T cells, casting doubt on the role of T cell AICD as
a major regulator of T cell clonal expansion in vivo. Impor-
tantly, the ratio of GZB-Cre.FasKI.OT-1 to OT-1 T cells re-
covered from the adoptive host in the cotransfer experi-
ment was 1.2:1.0 on day 7 and 0.9:1.0 on day 14 after
transfer, indicating that neither Fas-deficient OT-1 T cells
nor the recipient’s own T cells responding to L. monocyto-
genes infection killed Fas-positive OT-1 T cells (Figure 6C).
This result strongly argues against T cell ‘‘fratricide’’
(Crispe, 1994) as a negative regulatory mechanism.
Second, we asked whether Fas deficiency in T cells
contributes to development of systemic autoimmunity. It
takes more than 6 months for B6lpr/lpr mice to develop
the full autoimmune phenotype (lymphoproliferation,Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc. 633
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Fas Is Required for Elimination of APCsFigure 4. Deletion of Fas in DC Leads to Systemic Autoimmunity
(A) Detection of ANA in the sera of female CD11c-Cre.FasKI mice of the indicated ages tested at 1:100 dilution. Values are shown for individual mice.
Cre-negative FasKI littermates were used as controls.
(B) IgM and IgG detection by ELISA in sera of female 4272 CD11c.Cre-FasKI mice (green lines and bars) or their Cre-negative littermates (red lines and
bars). Left panels show relative concentration of Ig (OD in ELISA assay, lines represent individual mice); right panels show absolute concentrations of
IgG or IgM. Mean IgG concentrations ± SE were 7.0 ± 1.8 mg/ml in Cre-negative mice (n = 8) and 32.0 ± 11.8 mg/ml in CD11c-Cre.FasKI mice (n = 7).
IgM concentrations ± SE were 1.5 ± 0.7 mg/ml in Cre-negative mice (n = 3) and 5.6 ± 1.1 mg/ml in CD11c-Cre.FasKI mice (n = 7). The differences
between Cre-negative and Cre-positive mice were significant: p values for absolute concentrations were 0.04 and 0.05 for IgG and IgM, respectively.
Results for strain 4097 can be found in Figure S6.
(C) Expression of CD86 was tested in GFP-positive DCs from 6-month-old CD11c-Cre.FasKI mice (red line). Blue line, DCs from Fas-sufficient litter-
mates; thin lines, controls (no antibody).
(D) Spleen weights in 6-month-old strain 4272 CD11c-Cre.FasKI female mice were 74.0 ± 17.4 mg in Cre-negative littermates (n = 3) and 171.0 ±
21.5 mg in CD11c-Cre.FasKI mice (n = 3). Spleen weights ± SE in 5-month-old strain 4097 CD11c-Cre.FasKI female mice were 92.5 ± 1.0 mg in
Cre-negative littermates (n = 4) and 221.8 ± 54.2 mg in CD11c-Cre.FasKI mice (n = 5). In male 4097 CD11c-Cre.FasKI mice, spleen weights were
84.8 ± 2.4 mg in Cre-negative littermates (n = 7) and 186.5 ± 54.0 mg in CD11c-Cre.FasKI mice (n = 6). There was no significant difference between
female and male CD11c-Cre.FasKI spleen weights (p = 0.75).
(E) Spleens from Fas-sufficient littermates (a, c, e) and from CD11c-Cre.FasKI mice (b, d, f) were either formalin fixed, sectioned, and stained with
hematoxylin-eosin (a, b) or splenic cryostat sections were acetone fixed and stained with anti-CD11c-FITC and counterstained with CD8-PE (in c
and d) or anti-CD19-PE (in e and f).
(F) Livers from Fas-sufficient littermates (a) and from CD11c-Cre.FasKI mice were either formalin fixed and stained with hematoxylin-eosin (a–c) (c is
an enlargement of b), or their cryostat sections were acetone fixed and stained with anti-CD11c-FITC (d). Scale bars represent 100 mm.634 Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc.
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Fas Is Required for Elimination of APCsFigure 5. Autoimmunity in Mice with Fas Deletion in B Cells
(A) Splenic T and B cells from CD19-Cre.FasKI mice were stained with Fas antibodies. T and B cells from FasKO animals were used as negative
controls.
(B) Spleen weights were determined in >6-month-old CD19-Cre.FasKI mice and their Cre-negative littermates. Spleen weights (mean ± SE) in females
were 136.2 ± 11.1 mg in control mice (n = 5) and 518.1 ± 192.7 mg in CD19-Cre.FasKI mice (n = 7). In males, spleen weights were 142.6 ± 12.2 mg in
control mice (n = 11) and 674.0 ± 211.8 mg in CD19-Cre.FasKI mice (n = 5). Splenomegaly was not significantly different between females and males
(p = 0.6).
(C) The percent of CD4+ and CD8+ T cells and of B cells (B220+CD3 cells) ±SE in the lymph nodes and spleens of CD19-Cre.FasKI mice and control
littermates.
(D) The presence of ANA was tested in the sera (at 1:100 dilution) of 6+-month-old CD19-Cre.FasKI and Cre-negative littermate female mice. Relative
staining (mean score ± SE) was 1.6 ± 0.7 and 6.7 ± 0.8 in Cre and Cre+ FasKI mice, respectively. Dots represent sera from individual mice.production of autoimmune antibodies, and accumulation
of CD3+B220+ cells), and some of these features are
more pronounced in females (Theofilopoulos and Dixon,
1985; Warren et al., 1984a, 1984b). Therefore, mice com-
pared in these experiments were females 6 months old or
older. Sera from GZB-Cre.FasKI mice were tested for the
presence of ANA. Some animals showed high titers of
ANA compared to littermates (Figure 6E), indicating that
loss of Fas by activated T cells also leads to systemic
autoimmunity. Mice lacking Fas in activated T cells dem-
onstrated a slight but not significant increase in splenic
cellularity (Figure 6F). Lck-Cre.FasKI mice also developed
ANA (Figure 6G; Figure S5), without splenomegaly (see
Figure S8). Furthermore, we found that only mice with T
cell Fas deficiency, but not mice with APC Fas deficiency,
accumulated CD3+ (or Thy1.2+) B220+ double-positive
cells (Figures 7A and 7B). Accumulation of these cells in
GZB-Cre.FasKI mice (but not in Cre-negative FasKI con-
trols) suggests that they are indeed the progeny of previ-
ously activated T cells. The degree of variation in the num-
bers of CD3+B220+ cells in individual mice must reflect
their origin from T cells activated randomly by auto-
immune or environmental stimuli. Thy1.2+ cells expressing
B220 were analyzed further (Figures 7C and 7D). Fas
expression were compared for Thy1.2+B220 cells (gate
1) and Thy1.2+B220+ cells either expressing coreceptors
or not (gates 2a and 2b, respectively). T cells from GZB-
Cre.FasKI mice had shown progressive loss of Fas ex-
pression by T cells that acquired B220 and lost coreceptorexpression. Interestingly, in Cre-negative control FasKI
mice, Fas expression by Thy1.2+B220+, coreceptor-
negative cells was also diminished, but never reached
the amount of the negative control (lpr/lpr mice). Thus,
Fas deficiency limited to T cells also leads to systemic
autoimmunity, likely because of extended survival of
autoreactive T cells.
DISCUSSION
The genetic approach that we have taken by manipulation
of Fas expression in two different types of immune cells,
APCs and T cells, allowed us to conclude that both of
these subsets contribute to the Fas-dependent regulation
of autoimmunity. Accumulation of DCs in CD11c-Cre.
FasKI mice supports the idea that Fas-negative DCs
have escaped apoptotic death. Similarly, in a recent report
(Chen et al., 2006), systemic autoimmunity was detected
in mice with DCs overexpressing a transgenic caspase-
blocking viral protein that extended their survival. Here,
we demonstrate directly that the mechanism responsible
for DC elimination and preemption of autoimmunity is
based on Fas signaling.
Importantly, freshly isolated DCs were found not to ex-
press Fas uniformly, but Fas expression was induced by
maturation-stimulating cues: LPS, CpG, and type I inter-
feron. The requirement of DC activation through PRRs to
become sensitive to Fas and, hence, to removal by acti-
vated FasL-positive T cells, makes perfect sense for theImmunity 26, 629–641, May 2007 ª2007 Elsevier Inc. 635
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Fas Is Required for Elimination of APCsFigure 6. Loss of Fas by T Cells Does Not Regulate T Cell Responses to Strong Antigens, but Leads to Systemic Autoimmunity
(A) Fas expression by splenic T and B cells was compared between Lck-Cre.FasKI mice, their Cre-negative littermates, and FasKO animals used as
negative controls.
(B) Lck-Cre.FasKI, Cre-negative FasKI, and B6lpr/lprmice were immunized in the footpadswith 50 mgOVAmixed 1:1 with complete Freund’s adjuvant.
Regional lymph node cells were stimulated 11 days later in vitro overnight with OVA, and IFN-g secretion was detected by ELISPOT. Ordinate: mean
number of dots (from triplicate wells) is shown adjusted to the frequency of CD4+ T cells determined by flow cytometric analysis on the day of the
experiment. Symbols show individual mice. n: mice per group.
(C) GZB-Cre.FasKI.OT-1 transgenic Ly5.2 marked T cells and Ly5.1-marked OT-1 T cells were coinjected in Ly5.1+Ly5.2+ mice and their fate was
followed after infection with Lm-OVA. Details of experimental design are shown in Figure S7. Representative plots of the presence of Fas-negative
cells (%) is shown for T cells from GZB-Cre.FasKI.OT-1 donors (top) and Fas-suficient OT-1 T cells (middle), and the percentage of IFN-g producing
cells in both populations (bottom). Bold line indicates GZB-Cre.FasKI.OT-1 T cells; shaded histogram indicates OT-1 T cells from the same adoptive
host gated with Ly5 alleles. Absolute numbers of Cre-negative OT-1 versus GZB-Cre.FasKI.OT-1 T cells were 1.03 106 versus 1.23 106 on day 7 and
1.7 3 105 versus 1.6 3 105 on day 14, respectively.
(D) Primary (1) and secondary (2) responses to minor histocompatibility antigen H60 were compared in GZB-Cre.FasKI mice (closed symbols) and
Cre-negative littermates (open symbols). Ordinate: percent of CD8+ T cells in PBL that are H60-tetramer positive. Primary and secondary i.p. immu-
nizations with 2 3 107 C.B10 splenocytes are marked by arrows. Data shown for individual mice traced in two separate experiments (triangles and
squares, respectively).
(E) Sera from GZB-Cre.FasKI mice (n = 11) or Cre-negative littermates (n = 9) 6 months of age or older were used to detect ANA at 1:100 dilution.
Relative scores (mean ± SE) were 2.2 ± 0.4 and 6.3 ± 0.8 in Cre and Cre+ FasKI mice, respectively.
(F) Splenic cellularity (mean ± SE) was determined in 8- to 10-month-old GZB-Cre.FasKI (n = 19) mice and in control Cre-negative littermates (n = 9).
The difference between Cre-positive and Cre-negative littermates was not significant (p value was 0.215).
(G) Sera from individual 6+-month-old female Lck-Cre.FasKI mice (n = 13) mice and from control Cre-negative FasKI mice (n = 6) were tested for the
presence of ANA at 1:100 dilution. Relative scores (mean ± SE) were 5.3 ± 0.9 and 0.5 ± 0.3 in Cre+ FasKI and Cre mice, respectively.636 Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc.
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Fas Is Required for Elimination of APCsFigure 7. CD3+B220+ Cell Development Is T Cell Autonomous and Requires Prior T Cell Activation
(A) Examples of flow cytometric analyses showing the presence of CD3+B220+ cells in mice with Fas deletion in T cells (Lck-Cre.FasKI and GZB-Cre.
FasKI) and APCs (CD11c-Cre.FasKI and CD19-Cre.FasKI). All mice were 6+ months of age. Numbers shown in boxed areas are percent of
CD3+B220+ cells.
(B) The frequencies ofCD3+B220+ splenocyteswere determinedbyflowcytometry inmicewith conditional elimination of Fas fromDCs (strain 4272), B cells,
T cells, and activated T cells and in mice with systemic deletion of Fas (lpr/lpr). All animals were more than 6 months old. n, number of animals per group.
(C and D) Splenocytes from Cre-negative FasKI, GZB-Cre.FasKI, and B6lpr/lpr mice were stained with antibodies against Thy1.2 pan-T cell marker,
B220, and amixture of anti-CD4 and anti-CD8 labeled with the same fluorochrome (C). Gate 1, Thy1.2+, B220 cells; gate 2, Thy1.2+, B220+ cells. The
latter were electronically separated into Thy1.2+, B220+, coreceptor+ cells (Gate 2a) and Thy1.2+, B220+, coreceptor cells (Gate 2b). Gated cells were
further analyzed for Fas expression (D). Line color reflects mouse genotype (shown in [C]). Numbers within the plots are percent of cells within gated
populations.negative-feedback regulation and contraction of the T cell
response. Fas deficiency in DCs led to activation of other
cell types (splenomegaly was detected that could not be
explained by expansion of DCs alone), but did not pro-
duce double-negative T cells. Thus, Fas deficiency limited
to APC explains part of the phenotype observed in animals
with systemic Fas loss, and it is by itself sufficient to causeautoimmunity. It is also likely that FasL is not the only reg-
ulator of APC death: perforin deficiency has been shown
to cause familial histiocytosis (Stepp et al., 1999) and en-
hanced antigen response after multiple immunizations
with DCs (Yang et al., 2006). However, perforin-mediated
death of DCs can be blocked by maturation-induced
upregulation of a serpin protease inhibitor (MedemaImmunity 26, 629–641, May 2007 ª2007 Elsevier Inc. 637
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Fas Is Required for Elimination of APCset al., 2001). The cellular targets or timing for perforin- and
FasL-mediated killing of APCs may also differ. In this re-
spect, it is worth noting that autoimmune reactions were
observed in both CD11c-Cre.FasKI strains (4272 and
4097), despite substantial differences in transgene expres-
sion. Thus, this mechanism is indeed cell autonomous,
and minor APC populations resistant to one or another
apoptotic mechanism can contribute to autoimmunity.
Another important point is that although autoimmune
reactions such as production of ANA are accelerated in
B6.CD11c-Cre compared to B6lpr/lpr mice (no ANA could
be detected in the latter at 8–10 weeks of age, not shown),
their development is still gradual. That emphasizes the
random nature of autoimmune T cell activation.
It is currently unknown whether Fas-mediated APC
death contributes primarily to regulation of CD4+ and/or
CD8+ T cell responses, because CD4+ T cells need an
extended stimulation by APCs (Obst et al., 2005), whereas
CD8+ T cells may need a single hit (Bevan and Fink, 2001;
Mercado et al., 2000) or continuous stimulation (Curt-
singer et al., 2005; Storni et al., 2003) to be fully activated.
Analysis of two mouse strains, with Fas deleted in all T
cells or in activated T cells, revealed that Fas-negative T
cells are also capable of inducing systemic autoimmunity.
At the same time, we have established that Fas-negative T
cells gain no survival advantage over Fas-positive T cells
upon activation. The paradox can be solved by a proposi-
tion that responses to strong stimuli do not require Fas on
T cells for downregulation, whereas prevention of sys-
temic autoimmune reactions (when the supply of APCs
carrying weak but persistent autoantigens is unlimited)
requires both mechanisms: Fas-mediated negative regu-
lation of chronically activated T cells and Fas-mediated
elimination of activated APCs. The Fas independence of
the clonal contraction of T cells exposed to a strong stim-
ulus, bacterial superantigen (Hildeman et al., 2002), has
been previously established. We have found that re-
sponses to other more frequently occurring physiological
stimuli (nominal antigens and pathogens inducing strong T
cell responses) do not require Fas on T cells for clonal con-
traction, whereas responses to endogenous antigens did.
These endogenous antigens are likely to be weak stimuli,
simply because high-avidity responding T cells are re-
moved by central negative selection or tolerized in the pe-
riphery. Endogenous antigens persist, providing weak but
chronic stimulation to T cells. Activation of APCs by PRR
ligands may increase the chances for T cell activation,
alsomaking such activation a random event. That explains
the time-dependent development of autoimmune reac-
tions in mice lacking Fas in T cells, as well as in mice lack-
ing Fas in APCs.
In our experiments, Fas deficiency in T cells did not lead
to changes in animal viability or damage to internal organs
as previously reported (Hao et al., 2004). Lck-Cre.FasKI
and GZB-Cre.FasKI mice did not show significant loss of
body mass or spleen mass, with GZB-Cre.FasKI showing
a slight increase in splenic cellularity. In concordance with
a study by the Rajewsky group (Hao et al., 2004), in our
hands, CD4-Cre.FasKI mice did show weight loss and638 Immunity 26, 629–641, May 2007 ª2007 Elsevier Inc.mild lymphopenia. The reasons for the discrepancies
found in the two systems are not yet clear. One possibility
is that Fas deletion happens at different developmental
stages in CD4-Cre and Lck-Cre FasKI mice, leading to dif-
ferent consequences in terms of upregulation of FasL ex-
pression. Another possibility is that Fas actually provides T
cells with a survival signal (Park et al., 2005). That would
explain why NOD mice with Fas-negative T cells do not
develop diabetes, and possibly why B6.CD4-Cre.FasKI
mice had poor viability. Finally, the differences in micro-
flora in animal facilities may affect the lung pathology.
Thus, Fas-mediated AICD has no functional signifi-
cance for regulating the T cell responses to foreign anti-
gens, but is likely a mechanism specifically involved in
prevention of autoimmunity caused by chronic stimulation
of T cells with weak signals. Fas-mediated removal of
chronically activated T cells and activated APCs present-
ing self-antigens must act in concert to prevent systemic
autoimmunity.
It is also intriguing to learn whether the ability of APCs to
undergo a timely death regulates such phenomena as la-
tency of viral infections or organ-specific autoimmunity.
Knowledge of the precise mechanisms of T cell-induced
death of particular APC subsets would enable negative
regulation of autoimmunity, better vaccine development,
and improvement of immune responses to pathogens
and cancer.
EXPERIMENTAL PROCEDURES
Mice
Mice with Exon IX of Fas flanked with LoxP sites (Gu et al., 1993) (Fas
knockin, FasKI) were produced as shown in Figure S1. Animals with
Cre recombinase controlled by the proximal Lck promoter B6.Cg-
Tg(Lck-cre)548Jxm/J (Hennet et al., 1995) (Lck-Cre), by the CD19 pro-
moter C.129P2-Cd19tm1(cre)Cgn/J (Rickert et al., 1997) (CD19-Cre), and
by the granzyme B promoter B6;FVB-TgN(GZMB-Cre)1Jcb/J (Jacob
and Baltimore, 1999) (GZB-Cre) as well as C57BL6/J and Fas-negative
B6.129P2-Fastm1Osa/J (FasKO) mice were obtained from The Jackson
Laboratory. Fas-ligand-negative mice (Karray et al., 2004) were a
generous gift from S. Karray (Institut National de la Sante et de la
Recherche Medicale, Hopital Necker, Paris, France) and were bred
to OT-1 transgenic mice. To produce mice with Cre expressed under
control of the CD11c promoter, the Cre recombinase gene from
pBS185 plasmid (GIBCO-BRL) was introduced into the pIRES2-
EGFP plasmid (BD Biosciences Clontech, Palo Alto, CA), excised as
a Cre-IRES-GFP fragment, and subcloned into a plasmid containing
the 5.3 Kb genomic CD11c promoter/enhancer fragment (Brocker
et al., 1997) (a generous gift from K. Karjalainen, Institute for Research
in Biomedicine, Bellinzona, Switzerland). All mice were genotyped by
PCR with primers amplifying the Cre transgene (50-tgatgaggttcgcaa
gaacc-30 and 50-ccatgagtgaacgaacctgg-30) and Fas (50-gctgtgtctat
cagtct-30 and 50-agagacccacctctaggtag-30 ) generating 320 bp wild-
type and 400 bp ‘‘floxed’’ allele products. OT-1 mice carrying a
Va2/Vb5 transgene encoding an H-2Kb+OVA-specific T cell receptor
(Hogquist et al., 1994) were bred to B6.SJL-Ptprca Pepcb/BoyJ
mice carrying the Ly5.1 allele, whereas OT-1.FasKI.GzmB-Cre Tg
inherited the Ly5.2 allele. B6(Ly5.1xLy5.2) mice were bred on site.
Mice were housed at The Jackson Laboratory Research Animal
Facility, at The University of Chicago, and at the University of Washing-
ton under specific pathogen-free conditions, and all experiments
were performed in accordance with the institutional and national
guidelines.
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Labeled antibodies specific for Vb5 (MR9-4), Va2 (B20.1), CD8 (53-
6.7), NK1.1, CD49b (DX5) (used in the experiment shown in
Figure S3), CD95 (Fas, Jo2), and Fas ligand (MFL3) were obtained
from BD Biosciences Pharmingen (San Diego, CA). Anti-Ly5.1 (A20),
anti-Ly5.2 (104), and anti-CD11c-APC were purchased from eBio-
science (San Diego, CA). PCDA-1 antibodies were from Miltenyi
Biotech (Auburn, CA). Flow cytometric data were acquired with a
FACSCalibur flow cytometer (Becton-Dickinson, Mountain View,
CA). Data analysis was performed with CellQuest software (Becton-
Dickinson) and FlowJo software (Tree Star Inc., Ashland, OR). Anti-
nuclear antibodies were detected with HEp-2 substrate slides (RHI
Gene Inc., Des Plains, IL) according to the manufacturer’s instructions
with sera diluted 1:100. Every slide included a standard normal serum
from an 8-week-old B6 mouse (brightness = 0) and positive control
serum from a 1-year-old lpr/lpr mouse (brightness = 10). See also
Figure S4.
Histology and Immunohistochemistry
Tissues were fixed in picric acid-acetic acid-formalin and stained
with hematoxylin-eosin. Fresh-frozen acetone-fixed tissue sections
were stained with directly coupled anti-CD11c-FITC, anti-CD8-PE,
and anti-CD19 PE (all from Pharmingen) and immediately photo-
graphed with a Spot CCD camera (Diagnostic Instruments, Sterling
Heights, MA).
Listeria monocytogenes Infection
Frozen stocks of Lm engineered to express chicken ovalbumin
(Lm-OVA) (Foulds et al., 2002) (a gift from M. Bevan, University of
Washington) were made by passage through B6 mice for 48 hr. For
infection, a fresh aliquot of frozen Lm-OVA was grown in brain-heart
infusion broth (Difco, Sparks, MD) for 3–4 hr at 37C and diluted in ster-
ile PBS, and 2000 cfu was injected i.v. in a 200 ml volume.
T Cell Activation
Mice were immunized with 50 mg OVA in PBS mixed 1:1 with DIFCO
complete Freund’s adjuvant (BD Biosciences) into the hind footpads,
and popliteal lymph node cells were stimulated 11 days later with
10 mg/ml OVA. For stimulation, 2 3 105 responders were mixed with
3 3 105 irradiated splenocytes from TCRb-negative B6 mice
(B6.129P2-Tcrbtm1Mom/J, The Jackson Laboratory) and incubated
overnight in MultiScreen plates (Millipore, Bedford, MA), and IFNg pro-
duction was detected with the mouse IFNg ELISPOT pair from Phar-
mingen, according to the manufacturer’s instructions. Spots from trip-
licate cultures were counted manually, and the numbers were
normalized by the percent of CD4+ T cells to compensate for possible
loss of T cells. CD4+ T cells in the lymph nodes were enumerated by
flow cytometric analysis of anti-CD4-stained cells on the day of T
cell activation in vitro. CD8 cells did not contribute to IFNg production
under these experimental conditions. H60-reactive T cells were in-
duced by i.p. injection of 23 107 CB10/J splenocytes and enumerated
by staining with specific H60(LTFNYRNL)/Kb tetramers (a generous gift
of D. Roopenian, The Jackson Laboratory) used as described (Choi
et al., 2002).
Activation of DC and Killing Assays
Bone-marrow-derived DC were grown in the presence of GM-CSF as
described (Inaba et al., 1992), and on day 5, DC were incubated over-
night with 100 ng LPS (Sigma, St. Louis, MO) or 500 U/ml of recombi-
nant interferon-b (Pierce Biotechnology, Rockford, IL). To activate DC
in vivo, mice were injected with 50 ml of PBS per footpad containing
LPS (50 mg) or 20 mg of CpG (Coley Pharmaceutical Group, Wellesley,
MA). For the in vitro killing assay, DCwere activated with LPS as above
and plated on top of 105 either CT26 carcinoma cell line or CT26 trans-
fected with human FasL (CT26-CD95L) (Arai et al., 1997), a generous
gift from G. Nabel, NIH/VRC, in a well of a 24-well plate. After 12 hr
incubation, cells were collected, stained with antiCD11c-APC and pro-
pidium iodide (PI), and analyzed by flow cytometry. For the in vivo kill-ing assay, DCs were isolated by MACs technology with anti-CD11c
magnetic beads (Miltenyi Biotech), according to the manufacturer’s
instructions, from collagenase-DNase-treated spleens of either B6 or
B6lpr/lpr mice. DC were treated for 1 hr at 37C with 100 ng/ml of
SIINFEKL or with irrelevant peptide and 1 mg/ml LPS, stained with
1 mM (OT-1-treated) or 0.1 mM (irrelevant peptide-treated) carboxy-
fluoroscein succinimidyl ester (CFSE, Molecular Probes, Invitrogen,
Carlsbad, CA), washed, and injected as a 1:1 mixture (4 3 105 + 4 3
105 cells) into footpads of B6 mice. Mice were injected 24 hr later i.v.
with 1.5 3 106 CD8+ OT-1 T cells purified by positive selection with
magnetic beads. After 48 hr, DC from collagenase-DNase-treated
popliteal lymph nodes were stained for CD11c and analyzed by flow
cytometry. Percent cytotoxicity was estimated with the equation
100% 3 (a  b)/a, where ‘‘a’’ and ‘‘b’’ are the ratio between CFSElo
and CFSEhi cells before footpad injection and after recovery from the
lymph node, respectively. Similarly, for testing of cytoxicity in vitro,
BMDC fromB6 and B6lpr/lprmice were labeled with CFSE as described
above and cultured overnight in the presence of LPS (100 ng/ml) and
specific peptide (10 ng/ml of SIINFEKL peptide) with or without OT-1
or FasL.KO OT-1 T cells. Cells (5 3 104 of labeled DC and variable
numbers of T cells) were cultured in 0.5 ml of complete medium in
48-well plates in triplicates. DC from wells without peptide (CFSElo)
were mixed with DC from well containing the peptide (CFSEhi), stained
with CD11c antibodies, and analyzed by flow cytometery. Cytotoxicity
was calculated with the equation 100%3 (a b)/a, where ‘‘a’’ and ‘‘b’’
are the ratio between CFSElo and CFSEhi cells cultured without and
with T cells, respectively.
ELISA for Immunoglobulins
Relative concentrations of serum IgG and IgM were determined by
titrating sera from Cre-FasKI and control Cre-negative littermates into
wells of 96-well plates (Maxisorp, Nunc, Roskilde, Denmark) precov-
ered with anti-mouse Fab antibodies (Sigma) and blocked with 20%
FCS-PBS 2 hr at room temperature. Plates were incubated for 1 hr
at room temperature, washed, and incubated with either anti-mouse
Fcm or anti-Fcg antibodies conjugated to alkaline phosphatase,
washed, and developed with Sigma-104 phosphatase substrate
(Sigma). Dilutions of sera lower than 1:105 were saturating. Absolute
concentrations of IgG and IgM in sera were determined by comparison
with a standard mouse serum with defined Ig levels (Bethyl Laborato-
ries, Montgomery, TX). Graphic presentation and statistical analysis of
all data was performed with unpaired Student’s t test provided by
GraphPad Prism version 4.00c for OS X, GraphPad Software (San
Diego, CA).
Supplemental Data
Eight figures are available at http://www.immunity.com/cgi/content/
full/26/5/629/DC1/.
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